Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
ARCT Stock Chart & Stats
$6.63
-$1.70(-8.19%)
At close: 4:00 PM EST
$6.63
-$1.70(-8.19%)
Day’s Range― - ―
52-Week Range$5.85 - $24.17
Previous CloseN/A
Volume109.32K
Average Volume (3M)829.62K
Market Cap
$188.44M
Enterprise Value-$17.47M
Total Cash (Recent Filing)$230.91M
Total Debt (Recent Filing)$25.00M
Price to Earnings (P/E)―
Beta2.23
Next Earnings
May 11, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding28,423,069
10 Day Avg. Volume934,920
30 Day Avg. Volume829,622
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)0.78
Price to Sales (P/S)2.50
P/FCF Ratio-2.26
Enterprise Value/Market Cap-0.09
Enterprise Value/Revenue-0.24
Enterprise Value/Gross Profit-0.25
Enterprise Value/Ebitda0.24
Forecast
1Y Price Target
$17.32Price Target Upside161.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-4
Revenue Forecast (FY)$37.89M
Bulls Say, Bears Say
Bulls Say
Analyst Outlook And ValuationAnalyst recommendation remains BUY because the company's pipeline appears materially undervalued by the market, suggesting upside if clinical programs advance as expected.
Clinical Trial Design For Cystic FibrosisA redesigned 12-week cystic fibrosis cohort using stricter enrollment criteria and lung clearance index as an outcome aims to reduce variability and increase the chance of detecting a true treatment benefit.
OTC Deficiency Biomarker ResponseSecond-stage data in the ornithine transcarbamylase deficiency program showed reductions in a key biomarker and improved metabolic function, which could support regulatory discussions and act as a catalyst.
Bears Say
Efficacy Endpoint UncertaintyHigh-resolution imaging signs of mucus clearance have not reliably translated into improved lung function or quality of life, creating uncertainty about the program's ability to meet pivotal efficacy endpoints.
Management Credibility And ExecutionUneven execution and repeated setbacks have eroded management credibility, which can sustain a valuation discount until consistent delivery is demonstrated.
Trial Enrollment And Statistical Power RiskDividing a limited patient pool into dose-specific subgroups risks producing underpowered cohorts, increasing the likelihood that trials will fail to detect true treatment effects due to variability.
Arcturus Therapeutics News
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $5.85 and its highest was $24.17 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Arcturus Therapeutics’s market cap is $188.44M.
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s upcoming earnings report date is May 11, 2026 which is in 49 days.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on Mar 03, 2026. The company reported -$1.03 earnings per share for the quarter, missing the consensus estimate of -$0.777 by -$0.253.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics pays a Notavailable dividend of $0.06 which represents an annual dividend yield of N/A. See more information on Arcturus Therapeutics dividends here
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -1.01.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 28,423,069 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$1.03 in its last earnings report, missing expectations of -$0.777. Following the earnings report the stock price went down -4.172%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Currently, no hedge funds are holding shares in ARCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcturus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.32 (161.29% Upside)
$17.32 (161.29% Upside)
Hedge Fund Trend
Increased
By 738.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.29%
12-Months-Change
Fundamentals
Return on Equity
-27.43%
Trailing 12-Months
Asset Growth
-20.42%
Trailing 12-Months
Company Description
Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
ARCT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: several program and platform positives (UK approval for Costave, ARCT-2304 durable immune responses, ARCT-032 advancing to a 12‑week Phase II, ARCT-810 moving toward pivotal discussions) alongside significant near-term financial and commercial challenges (material year-over-year revenue declines, reduced cash balance, ongoing CSL collaboration uncertainty, and early-stage clinical efficacy data in small cohorts). Management highlighted expense reductions and extended runway to Q2 2028, but commercial/regulatory clarity (especially in the U.S. for Costave) and larger clinical datasets are needed to materially de-risk the outlook.View all ARCT earnings summariesARCT Stock 12 Month Forecast
Average Price Target
$17.32
▲(161.29% Upside)
Technical Analysis
Rigel
―
Arvinas Holding Company
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Erasca
―
Ownership Overview
8.04% Insiders
29.13% Mutual Funds
29.60% Other Institutional Investors
12.80% Public Companies and Individual Investors